19314-10-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-CHLORO-N-(4-HYDROXYPHENYL)PROPIONAMIDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of various bioactive molecules and pharmaceuticals. The presence of the chloro and hydroxyphenyl groups enhances its reactivity and potential for creating diverse medicinal compounds.
Used in Agrochemical Production:
In the agrochemical industry, 3-CHLORO-N-(4-HYDROXYPHENYL)PROPIONAMIDE is utilized as a precursor in the synthesis of agrochemicals, where its unique structure can be leveraged to create compounds with specific pesticidal or herbicidal properties.
Used in Organic Chemistry Research:
3-CHLORO-N-(4-HYDROXYPHENYL)PROPIONAMIDE is also used as a research compound in the field of organic chemistry, where its properties and potential applications are still being explored. It serves as an important tool for understanding reaction mechanisms and developing new synthetic pathways.
3-CHLORO-N-(4-HYDROXYPHENYL)PROPIONAMIDE's multifaceted applications underscore its significance in both the chemical and pharmaceutical sectors, with ongoing research aimed at unlocking further uses and refining its role in the synthesis of novel compounds.

InChI:InChI=1/C9H10ClNO2/c10-6-5-9(13)11-7-1-3-8(12)4-2-7/h1-4,12H,5-6H2,(H,11,13)

Upstream product

• 123-30-8 4-amino-phenol 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 54197-66-9 3,4-dihydro-6-hydroxy-2(1H)-quinolinone 

Relevant academic research and scientific papers

SUBSTITUTED BENZOLACTAM COMPOUNDS

This invention relates to compounds of general formula (I): or a pharmaceutically acceptable salt thereof, W, T, Y, X, Q, R, R, and R are defined herein. This invention also relates to compounds of formula (I), depicted above, wherein Y is -NH-; T is (2S,3S)-2-phenylpiperidin-3-yl, where the phenyl group of said (2S, 3S)-2-phenylpiperidine-3-yl may optionally be substituted with fluoro; Q is oxygen and is double bonded to the carbon atom to which it is attached, X is methoxy or ethoxy, R is hydrogen, methyl or halo-C1-C2 alkyl, W is methylene, ethylene or vinylene; R and R are independently hydrogen or methyl, or one of R or R may be hydroxy, when W is ethylene, R and R are both methyl, when W is methylene, and R and R are both hydrogen, when W is vinylene. The invention is further directed to methods of treating various CNS and other disorders using said compounds and pharmaceutical compositions thereof.

Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5α-reductase 1

New 5α-reductase 1 (5αR-1) inhibitors were designed to complete a consistent set of analogues suitable for a 3D QSAR study. These compounds were synthesized by a modification of the aza-Robinson annulation, further functionalized by Pd-catalyzed cross-coupling processes, and were tested with human 5αR-1 expressed in Chinese hamster ovary 1827 cells. It turned out that the potency of the resulting inhibitors was strongly dependent on the type of substitution at the 8 position, with the 1C50 values ranging from 8.1 to 1050 nM. The construction of this homogeneous set of molecules allowed a 3D QSAR study. In particular, comparative molecular field analysis (CoMFA) was used to correlate the potency of the inhibitors with their physicochemical features. Highly accurate evaluations of the atomic point charges were carried out by means of quantum chemical calculations at the DFT/B3LYP level of theory followed by the RESP fitting procedure. It turned out that increasing the reliability of electrostatic parameters greatly affected the statistical results of the QSAR analysis. The 3D QSAR model proposed could be very useful in the further development of 5αR-1 inhibitors, which are suitable candidates to be evaluated as drugs in the treatment of 5αR-1 related diseases such as acne and alopecia in men and hirsutism in women.